GlassScriptPhysician profile
Bertha C Fonseca
NPI 1851592729
$370,967.22
in general payments reported to CMS, 2019-2025
26 companies · $34K in 2025
The $34K reported for 2025 was more than what 95% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82K · 2020: $42K · 2021: $35K · 2022: $90K · 2023: $46K · 2024: $42K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $102K · Food and Beverage: $6,732 · Travel and Lodging: $5,829 · Honoraria: $5,100 · Consulting Fee: $1,886 · Education: $24.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $102,150.50 |
| Food and Beverage | $6,732.15 |
| Travel and Lodging | $5,829.36 |
| Honoraria | $5,100.00 |
| Consulting Fee | $1,886.00 |
| Education | $24.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $152,892.92 | 2019-2025 | Vumerity, Tysabri, Tysabri |
| Emd Serono, INC. | $114,593.22 | 2019-2025 | Mavenclad, Mavenclad |
| Horizon Therapeutics Plc | $38,195.73 | 2021-2023 | Uplizna |
| E.R. Squibb & Sons, L.L.C. | $15,925.00 | 2021-2022 | |
| Genzyme Corporation | $14,545.89 | 2019-2025 | |
| Celgene Corporation | $11,064.21 | 2020-2025 | Zeposia |
| Novartis Pharmaceuticals Corporation | $9,955.25 | 2019-2025 | Kesimpta |
| Teva Pharmaceuticals USA, INC. | $8,005.78 | 2019 | |
| Banner Life Sciences, LLC | $3,806.72 | 2022-2024 | |
| Abbvie INC. | $403.83 | 2022-2023 | |
| Genentech USA, INC. | $345.22 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Eisai INC. | $242.88 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $212.70 | 2020-2025 | Acthar |
| Tg Therapeutics, INC. | $130.64 | 2025 | |
| Mallinckrodt Enterprises LLC | $122.94 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $89.99 | 2021 | |
| Acorda Therapeutics, INC | $79.78 | 2019 | |
| Alexion Pharmaceuticals, INC. | $68.27 | 2019 | |
| Vertical Pharmaceuticals, LLC | $62.40 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $49.19 | 2022-2025 | |
| Allergan, INC. | $47.48 | 2020 | |
| Cycle Pharmaceuticals INC | $44.27 | 2025 | Bafiertam |
| Pfizer INC. | $25.63 | 2024 | |
| Adamas Pharmaceuticals, INC. | $24.60 | 2019 | |
| Merz Pharmaceuticals, LLC | $18.13 | 2025 | Inbrija, Ampyra |
| Vanda Pharmaceuticals INC. | $14.55 | 2025 | Ponvory |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bertha Fonseca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.